# Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

> **NCT02966028** · PHASE2 · COMPLETED · sponsor: **Sanifit Therapeutics S. A.** · enrollment: 274 (actual)

## Conditions studied

- Cardiovascular Diseases
- Cardiovascular Abnormalities
- Calcifications, Vascular
- Endstage Renal Disease
- ESRD
- Coronary Artery Calcification

## Interventions

- **DRUG:** SNF472
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02966028
- **Lead sponsor:** Sanifit Therapeutics S. A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-08
- **Final completion:** 2019-09
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2021-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966028, "Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02966028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*